Literature DB >> 16388958

Left ventricular reconstruction benefits patients with ischemic cardiomyopathy and non-viable myocardium.

Gustavo Aguiar Ribeiro1, Cledicyon Eloy da Costa, Mauricio M Lopes, Ana Nunes Albuquerque, Fernando Antoniali, Gleice Agnes A Reinert, Kleber G Franchini.   

Abstract

OBJECTIVE: There are subsets of patients with ischemic cardiomyopathy for whom the optimal treatment strategies are not clear. The objective of this study was to delineate the relationship between clinical outcomes and surgical procedure in patients who were treated either with a coronary artery bypass graft or with a coronary artery bypass graft and additional ventricular restoration.
METHODS: The study population comprised 137 consecutive patients with anterior myocardial infarction. All patients had an ejection fraction <50% and left ventricle end-systolic volume index >80 ml/m(2). The patients were divided into a viable and a non-viable group according to anterior myocardium viability, which was determined by a thallium-201 test. The viable group underwent a revascularization and was randomized into two groups for additional ventricular reconstruction. Group 1a comprised 35 patients with viable anterior wall who underwent surgical revascularization. Group 1b comprised 39 patients with viable anterior wall who underwent surgical revascularization and ventricular restoration. Group 2 comprised 69 patients with non-viable anterior wall who underwent revascularization and ventricular reconstruction. The preoperative and postoperative ejection fractions, end-systolic volume, mitral regurgitation, mortality, and heart failure symptoms were compared among groups.
RESULTS: Complete 2-year follow-up was achieved in 127 (92.7%) patients. Ejection fraction improved in all groups compared with preoperative values and it was greater in group 1b than in group 1a (p<0.001) at 2 years. There were no postoperative deaths in group 1a, one in group 1b, and two in group 2. After 2 years, group 1b was significantly smaller than group 1a (p<0.01) in relation to mitral regurgitation of grades 1 to 2+. End-systolic volume was significantly smaller in group 1b than in group 1a (p<0.001), it was smaller in group 1a than in group 2 (p<0.001), and it was smaller in group 1b than in group 2 (p<0.001). Heart failure class (NYHA) was reduced in all groups and events were significantly smaller in patients with end-systolic volume lesser than 120 ml/m(2) (p<0.05).
CONCLUSION: We have demonstrated that the short-term and mid-term outcomes of coronary artery surgery alone in patients with a large left ventricle are inferior to coronary artery surgery plus ventricular restoration.

Entities:  

Mesh:

Year:  2006        PMID: 16388958     DOI: 10.1016/j.ejcts.2005.11.023

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

1.  Mid-term results of coronary bypass graft surgery in patients with ischaemic left ventricular systolic dysfunction and no detected myocardial viability.

Authors:  Jun Liu; Zixiong Liu; Anqing Chen; Zhe Wang; Mi Zhou; Junfeng Cai; Qiang Zhao
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-02-23

2.  Surgical ventricular reconstruction for ischaemic heart failure: state of the art.

Authors:  Serenella Castelvecchio; Andrea Garatti; Pier Vincenzo Gagliardotto; Lorenzo Menicanti
Journal:  Eur Heart J Suppl       Date:  2016-04-29       Impact factor: 1.803

Review 3.  Surgical left ventricular reconstruction.

Authors:  Tadashi Isomura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-05-06

4.  Surgical ventricular restoration to reverse left ventricular remodeling.

Authors:  Serenella Castelvecchio; Lorenzo Menicanti; Marisa Di Donato
Journal:  Curr Cardiol Rev       Date:  2010-02

5.  Surgical Ventricular Restoration: An Operation to Reverse Remodeling - Clinical Application (Part II).

Authors:  Ganesh Shanmugam; Imtiaz S Ali
Journal:  Curr Cardiol Rev       Date:  2009-11

6.  MEF2C repressor variant deregulation leads to cell cycle re-entry and development of heart failure.

Authors:  Ana Helena M Pereira; Alisson C Cardoso; Silvio R Consonni; Renata R Oliveira; Angela Saito; Maria Luisa B Vaggione; Jose R Matos-Souza; Marcelo F Carazzolle; Anderson Gonçalves; Juliano L Fernandes; Gustavo C A Ribeiro; Mauricio M Lopes; Jeffery D Molkentin; Kleber G Franchini
Journal:  EBioMedicine       Date:  2020-01-03       Impact factor: 8.143

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.